R

    Rocket Pharmaceuticals Inc (RCKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.72
    -0.14 (-3.63%)

    Market Cap: $408.36M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    -5.52%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.40
    Range$-0.43 - $-0.35
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.44-8.3%
    60d ago$-0.43-6.8%
    30d ago$-0.43-6.8%
    7d ago$-0.43-6.8%
    Current$-0.40
    Revenue Consensus
    $222220
    Range$0 - $2M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.48
    Range$0.38 - $0.66
    4 analysts
    Revenue Consensus
    $-15660420
    Range$-16767670 - $-11767670
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.48---
    Sep 26EST
    		-$-0.40---
    Jun 26
    Reported Aug 6
    		$-0.15$0.28-153.57%Miss+74.6%
    Mar 26
    Reported May 7
    		$-0.42$-0.45+6.67%Beat+25.0%
    Dec 25
    Reported Feb 26
    		$-0.38$-0.42+9.52%Beat+38.7%
    Sep 25
    Reported Nov 6
    		$-0.45$-0.52+13.46%Beat+36.6%
    Jun 25
    Reported Aug 7
    		$-0.59$-0.57-3.51%Miss+20.3%
    Mar 25
    Reported May 8
    		$-0.56$-0.58+3.45%Beat+15.2%
    Dec 24
    Reported Feb 27
    		$-0.62$-0.72+13.64%Beat+3.1%
    Sep 24
    Reported Nov 7
    		$-0.71$-0.75+5.33%Beat+5.3%
    Jun 24
    Reported Aug 5
    		$-0.74$-0.72-2.78%Miss+9.8%
    Mar 24
    Reported May 6
    		$-0.66$-0.68+2.94%Beat+9.6%
    Dec 23
    Reported Feb 26
    		$-0.64$-0.77+16.88%Beat+28.1%
    Sep 23
    Reported Nov 6
    		$-0.75$-0.78+3.85%Beat+13.8%
    Jun 23
    Reported Aug 10
    		$-0.82$-0.78-5.13%Miss+1.2%
    Mar 23
    Reported May 4
    		$-0.73$-0.85+14.12%Beat-9.0%
    Dec 22
    Reported Feb 27
    		$-0.89$-0.82-8.54%Miss-29.0%
    Sep 22
    Reported Nov 3
    		$-0.87$-0.77-12.99%Miss-10.1%
    Jun 22
    Reported Aug 8
    		$-0.83$-0.68-22.06%Miss-50.9%
    Mar 22
    Reported May 5
    		$-0.67$-0.71+5.63%Beat-3.1%
    Dec 21
    Reported Feb 24
    		$-0.69$-0.73+5.48%Beat+36.1%
    Sep 21
    Reported Nov 3
    		$-0.79$-0.62-27.42%Miss-49.1%
    Jun 21
    Reported Aug 9
    		$-0.55$-0.65+15.38%Beat-22.2%
    Mar 21
    Reported May 10
    		$-0.65$-0.69+5.80%Beat-44.4%
    Dec 20
    Reported Feb 25
    		$-1.08$-0.50-116.00%Miss-176.9%
    Sep 20
    Reported Nov 4
    		$-0.53$-0.45-17.78%Miss-39.5%
    Jun 20
    Reported Aug 5
    		$-0.45$-0.50+10.00%Beat-18.4%
    Mar 20
    Reported May 6
    		$-0.45$-0.45+0.00%Beat-4.7%
    Dec 19
    Reported Mar 5
    		$-0.39$-0.49+20.41%Beat+40.9%
    Sep 19
    Reported Nov 7
    		$-0.38$-0.51+25.49%Beat+5.0%
    Jun 19
    Reported Aug 7
    		$-0.38$-0.61+37.70%Beat+5.0%
    Mar 19
    Reported May 8
    		$-0.43$-0.62+30.65%Beat-53.6%
    Dec 18
    Reported Mar 7
    		$-0.66$-0.44-50.00%Miss+8.3%
    Sep 18
    Reported Nov 7
    		$-0.40$-0.44+9.09%Beat-48.1%
    Jun 18
    Reported Aug 8
    		$-0.40$-0.44+9.09%Beat+58.3%
    Mar 18
    Reported May 11
    		$-0.28$-0.39+28.21%Beat+82.5%
    Dec 17
    Reported Mar 7
    		$-0.72$-0.31-132.26%Miss+62.5%
    Sep 17
    Reported Nov 8
    		$-0.27$0.00N/ABeat+83.5%
    Jun 17
    Reported Aug 3
    		$-0.96$-1.88+48.94%Beat-
    Mar 17
    Reported May 10
    		$-1.60$-1.57-1.91%Miss-
    Dec 16
    Reported Mar 16
    		$-1.92$-1.73-10.98%Miss-
    Sep 16
    Reported Nov 9
    		$-1.64$-1.78+7.87%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.66EV/EBITDA46.63x
    Price/FCF-2.46xFCF Yield-40.62%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-4.77%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-6.74x
    Current Ratio9.24xQuick Ratio9.24x
    Trading Statistics
    Beta0.47Avg Volume1.60M
    52-Week High$5.4552-Week Low$2.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.62
    SMA 20$3.55
    SMA 50$3.52
    SMA 200$3.56
    EMA 10$3.64
    EMA 20$3.57
    EMA 50$3.49
    EMA 200$3.70

    MACD

    Line: 0.08Signal: 0.05Hist: 0.03

    ADX

    ADX: 15.3+DI: 27.2-DI: 13.0

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down20.0
    PSAR$3.33

    Bollinger Bands

    Upper Band$3.83
    Lower Band$3.27
    %B Position1588%(Upper)
    Band Width0.80

    RSI (14-Day)

    Neutral
    56.1

    Momentum Oscillators

    Stoch %K69.8
    Stoch %D73.3
    Williams %R-37.5
    ROC (10d)9.4%
    Momentum0.32
    CCI (20d)120.4
    MFI (14d)47.3

    Volatility Measures

    ATR (14d)$0.22(5.8%)
    StdDev (20d)0.14
    Hist Vol60.9%(High)

    Volume Flow

    VWAP$3.72
    OBV-25.1M
    AD Line-117.4M
    CMF (20d)0.156

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio1.1x
    VWMA (20d)$3.58

    Pivot Points

    R3$4.52
    R2$4.25
    R1$4.06
    Pivot Point$3.79
    S1$3.60
    S2$3.33
    S3$3.14

    Advanced Oscillators

    TSI10.86
    Ultimate Osc57.8
    KST37.65

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$9.19M$0$0$0$10.31M$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$5.16M$0
    Gross Profit$0$0N/A$0$0$0$4.59M$0$0$0$5.16M$0
    Operating Expenses$46.92M$48.51M$43.96M$52.25M$71.15M$64.39M$62.69M$69.42M$73.71M$67.38M$63.28M$65.43M
    R&D$29.50M$31.45M$29.35M$34.07M$42.66M$35.94M$37.36M$42.31M$46.34M$45.23M$41.74M$46.84M
    SG&A$17.43M$17.06M$14.68M$18.35M$25.02M$28.45M$25.34M$27.11M$27.37M$22.15M$21.54M$18.59M
    Operating Income$-46,922,000$-48,511,000$-43,963,000$-52,247,000$-71,149,000$-64,388,000$-62,694,000$-69,424,000$-73,712,000$-67,375,000$-63,279,000$-65,429,000
    Interest Income$347,000$161,000$690,000$709,000$483,000$1.34M$1.62M$1.33M$2.29M$3.03M$814,000$1.72M
    Interest Expense$473,000$473,000$473,000$473,000$473,000$472,000$473,000$471,000$471,000$471,000$470,000$469,000
    Income Before Tax$131.84M$-48,823,000$-43,746,000$-52,011,000$-68,919,000$-63,524,000$-61,550,000$-68,568,000$-71,889,000$-64,817,000$-62,935,000$-64,178,000
    Income Tax Expense$8.62M$0$0$0$0$0$0$0$0$0$0$0
    Net Income$123.21M$-47,594,000$-42,538,000$-50,332,000$-68,919,000$-61,334,000$-60,327,000$-66,719,000$-69,646,000$-62,054,000$-59,660,000$-61,899,000
    EBITDA$134.06M$-46,365,000$-42,834,000$-50,606,000$-68,562,000$-63,474,000$-61,556,000$-68,884,000$-73,583,000$-67,875,000$-71,512,000$-58,839,000
    EBIT$131.96M$-48,511,000$-43,963,000$-52,247,000$-68,929,000$-64,388,000$-62,694,000$-69,424,000$-73,712,000$-67,375,000$-63,279,000$-65,429,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RCKT

    News

    Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating

    Chardan has initiated coverage on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) with a Buy rating and an $11.00 price target, highlighting the stock's substantial upside from its current trading price of $3.72. The gene therapy company, soon to be commercial-stage, recently monetized its Kresladi Priority Review Voucher for $180 million, providing a strong cash runway into Q2 2028. Rocket Pharmaceuticals is also engaging with the FDA regarding its key drug candidate, RP-A501, for Danon disease, with regulatory and program updates expected in the latter half of 2026.

    Investing.com•9/1/26•
    Bullish

    Rocket Pharmaceuticals Establishes New Severance and Executive Agreements

    Rocket Pharmaceuticals (RCKT) has implemented a new tiered severance and change-in-control program for most U.S. employees, offering defined salary and healthcare continuation benefits, especially around corporate control changes. Concurrently, the company formalized and amended executive employment agreements for its CEO, general counsel, and COO, setting specific pay, bonus, and severance terms. These actions aim to strengthen leadership protections and clarify outcomes during potential restructuring or M&A events, though TipRanks' AI Analyst "Spark" rates RCKT as Neutral due to weak financial performance despite improved liquidity and positive technical momentum.

    TipRanks•8/27/26•
    Neutral

    Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock

    Martin Wilson, General Counsel at Rocket Pharmaceuticals, Inc., sold 631 shares of the company's common stock for $2,133 on August 18, 2026, to cover tax obligations. Following the sale, Wilson beneficially owns 673,853 shares. The company recently completed the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million and held its 2026 Annual Meeting of Stockholders.

    Investing.com•8/21/26•
    Neutral

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts

    Rocket Pharmaceuticals (NASDAQ: RCKT) has received an average "Hold" rating from analysts, with a diverse range of recommendations including sell, hold, buy, and strong buy. The stock is under pressure, with shares down 4.7% and a market capitalization of approximately $382 million, though it recently beat EPS estimates. Institutional ownership is high at 98.39%, and insider selling has occurred to cover tax obligations.

    MarketBeat•8/21/26•
    Neutral

    Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares

    Rocket Pharmaceuticals CEO Gaurav Shah sold 2,293 shares of the company's common stock for $7,752 to cover tax withholding obligations from Restricted Stock Unit vesting. Despite the sale, Shah retains a significant stake in the company. Rocket Pharmaceuticals recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and held its annual meeting, while analysts maintain a "Hold" rating on its stock.

    Investing.com•8/21/26•
    Neutral

    Frequently Asked Questions About RCKT

    Does RCKT pay dividends?
    Rocket Pharmaceuticals Inc (RCKT) does not currently pay a regular dividend.
    What is RCKT's market cap?
    Rocket Pharmaceuticals Inc (RCKT) has a market capitalization of $408.36M with a current stock price of $3.72.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In